GDD to produce world leading cancer medicine by 2020

The pharmaceutical production base of InnoCare Guangzhou in Sino-Singapore Guangzhou Knowledge City (SSGKC) in Guangzhou Development District (GDD) finished the construction of its major structure on Jan 21.

The base, which is being designed to have an annual production capacity of one billion pills, is expected to finish equipment testing and start trial operation in 2020. It will gradually undertake the research and development, as well as the production of the company's new medicine projects and international new medicine cooperation projects. 

InnoCare is a company with the global vision to discover and develop novel treatments for cancer and autoimmune diseases. It boasts an elite scientific advisory board (SAB) comprised of professionals from leading universities, hospitals, academic institutions, and the pharmaceutical industry.

"It only cost us one year and a half from the settling down of the project to the completion of its major structure, thanks to the support and convenient services offered by GDD," said Jasmine Cui, president and CEO of InnoCare.

Cui said that the base will attach great importance to manufacturing quality, bringing more Chinese treatment solutions to patients around the world.

InnoCare will expand its business in areas like R&D, marketing, and talent cultivation in Guangzhou in the future to establish a full industrial chain featuring manufacturing, learning, and research based on mutual cooperation.

An innovative pharmaceutical preparation center will also be built in the area to serve other companies in the region to boost their development.

The pharmaceutical production base of InnoCare Guangzhou in GDD finishes the construction of its major structure on Jan 21. [Photo by Li Zhiwei/southcn.com]